The essential job of precision medicine is to match the right drugs to the right patients. In cancer, precision medicine has been nearly synonymous with genomics. However, sobering recent studies have generally shown that most patients with cancer who receive genomic testing do not benefit from a genomic precision medicine strategy. Although some call the entire project of precision cancer medicine into question, I suggest instead that the tools employed must be broadened. Instead of relying exclusively on big data measurements of initial conditions, we should also acquire highly actionable functional information by perturbing—for example, with cancer therapies—viable primary tumor cells from patients with cancer.
Read full article here: https://www.nature.com/articles/nm.4389
The Scientist, February 22, 2018
Cell. 2018 Jan 11;172(1-2):373-386.
Trends Mol Med. 2017 May;23(5):393-410.
Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):E6831-E6839.
Nature. 2016 Nov 24;539(7630):560-564.
Nat Mater. 2016 Mar;15(3):344-52
Subscribe to our newsletter
Stay up-to-date on the latest advancements in 3D cell culture technology